December 2014

New Product - Xeomin

Xeomin (incobotulinumtoxinA) is produced from the fermentation of Clostridium botulinum and is subsequently purified to remove complexing proteins. IncobotulinumtoxinA blocks cholinergic transmission at the neuromuscular junction by inhibiting the release of acetylcholine from peripheral cholinergic nerve terminals. Xeomin is indicated for use for the treatment of cervical dystonia in adults; blepharospasm in adults; post-stroke spasticity of the upper limb in adults; and in glabellar frown lines in adults. Xeomin is contraindicated in generalised disorders of muscle activity (e.g. myasthenia gravis, Lambert-Eaton syndrome) and in infection or inflammation at the proposed injection sites. Xeomin is available as 50 LD₅₀ units and 100 LD₅₀ units in single glass vials.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au